Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.08 EUR
Change Today +0.008 / 0.20%
Volume 0.0
RN3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 10:10 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

arena pharmaceuticals inc (RN3) Snapshot

Open
€4.07
Previous Close
€4.08
Day High
€4.19
Day Low
€4.00
52 Week High
01/14/15 - €5.19
52 Week Low
10/14/14 - €2.62
Market Cap
985.9M
Average Volume 10 Days
712.5
EPS TTM
--
Shares Outstanding
241.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARENA PHARMACEUTICALS INC (RN3)

arena pharmaceuticals inc (RN3) Related Businessweek News

View More BusinessWeek News

arena pharmaceuticals inc (RN3) Details

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. It is also developing a portfolio of programs in various therapeutic areas, including cardiovascular, central nervous system, and metabolic diseases. Its products under development include Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, including potentially pulmonary arterial hypertension that is in Phase II clinical trials. The company’s products under development also comprise APD334, an modulator of the sphingosine 1-phosphate subtype 1 receptor for the treatment of a various autoimmune diseases, which has completed Phase I single-ascending dose trials; APD371, an agonist of the cannabinoid receptor 2 that is in Phase I clinical trials intended for the treatment of pain and fibrotic diseases; and Temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I clinical trials. In addition it manufactures drug products under a toll manufacturing agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.

325 Employees
Last Reported Date: 03/2/15
Founded in 1997

arena pharmaceuticals inc (RN3) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $725.0K
Co-Founder, Executive Vice President, Chief S...
Total Annual Compensation: $420.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $395.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2013.

arena pharmaceuticals inc (RN3) Key Developments

Eisai Inc. and Arena Pharmaceuticals, Inc. Complete Registrational Trials of an Extended Release Formulation of Lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. If approved, the extended release formulation is expected to be marketed as BELVIQ XR, which is the brand name conditionally approved by the FDA. Each of the two randomized, crossover trials evaluated the safety, tolerability, pharmacokinetics and bioavailability of an extended release formulation of lorcaserin in 36 healthy adult subjects. Patients in each trial were divided into two treatment groups and received both doses in a two-way crossover sequence. Patients in the first study were dosed under fasted conditions either 10 mg twice-daily immediate release or 20 mg once-daily extended release. Patients in the second study were dosed either 20 mg QD extended release in the fasted state or 20 mg QD extended release in the fed state. The most common treatment-emergent adverse events were similar to those seen in the Phase 3 clinical trials of BELVIQ, and included mild or moderate headache, constipation, dizziness and nausea. There were no discontinuations for adverse events, and no serious adverse events were observed. Lorcaserin extended release formulation is investigational and not approved by any regulatory agency.

Arena Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 12:50 PM

Arena Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 12:50 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Arena Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year of 2015

Arena Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $32.1 million, or $0.15 loss per diluted share, compared with the prior-year period's $23.5 million or $0.11 loss per diluted share. Total revenue was $9.2 million, up from $6.5 million in the same quarter last year. For the year, the company reported net loss of $60.51 million against $19.43 million a year ago. Diluted loss per share was $0.28 against $0.09 a year ago. Total revenue was $36.97 million against $81.39 million a year ago. 2013 revenues were higher than 2014 revenues, primarily because in 2013, the company earned $65 million of milestone payments from Eisai in connection with the final scheduling destination for BELVIQ. The company said that for 2015, it expects majority of its revenues to be payments from collaborators based on their net product sales of BELVIQ. ARNA expects to receive 31.5% and 35% of Eisai's and Ildong's net product sales of BELVIQ, respectively. Arena is currently not able to predict the amount of these sales and, accordingly, is not providing guidance for its overall 2015 revenues at this time. A lesser amount of Arena’s total 2015 revenues will consist of regulatory milestones (including the $3.0 million milestone achieved from the approval of BELVIQ in South Korea in February 2015), amortization of upfront payments from existing collaborations (expected to be approximately $8.0 million), development and patent reimbursements from Eisai (expected to be approximately $7.0 million), and toll manufacturing from Siegfried (expected to be approximately $1.0 million). The company expects full year 2015 research and development expenses of approximately $114.0 million to $122.0 million, including non-cash expenses of approximately $13.0 million and $6.0 million in development expenses reimbursed by Eisai (with such reimbursed expenses included in revenue). In addition, the company expects to spend approximately $8.0 million to $9.0 million for capital expenditures, primarily related to its manufacturing facility in Switzerland. Arena may moderate its planned level of expenses based on its revenues and shared costs with collaborators.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RN3:GR €4.08 EUR +0.008

RN3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.71 USD +0.095
Array BioPharma Inc $7.19 USD -0.12
Orexigen Therapeutics Inc $7.36 USD -0.08
Progenics Pharmaceuticals Inc $6.03 USD -0.375
Rigel Pharmaceuticals Inc $4.88 USD +0.55
View Industry Companies
 

Industry Analysis

RN3

Industry Average

Valuation RN3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.7x
Price/Book 20.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.